English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the current study, it was tried to design and synthesize a new derivative of β-cyclodextrin (β-CD) as a result of reaction with D-maltose (β-CD-M) to compare and investigate its capability as an anticancer drug nanocarrier. The success in the β-CD-M synthesis was validated via common characterization techniques: nuclear magnetic resonance (NMR), Fourier transform infrared spectroscopy (FT-IR), and scanning electron microscopy (SEM). The SEM results indicate that the obtained β-CD-M molecule has a crystalline structure with a size of less than 100 nm. In the following, methotrexate (MTX) and doxorubicin (DOX) as the model of anticancer drugs were separately loaded in β-CD-M and their release profile was obtained. The outcome of the cytotoxic assay against MCF 10A cells indicated that β-CD-M is biocompatible and could be used as a drug carrier. Overall, from the obtained results, the synthesized biocompatible β-CD-M with more drug loading capacity and a controlled release profile in comparison to unmodified β-CD could be proposed as a potential nanocarrier for anticancer drug delivery.

Cluster of D-maltose clicked to β-cyclodextrin: preparation and its application as a biocompatible drug delivery nanovehicle